Pharmaceutical company Lumosa Therapeutics has announced positive results from its Phase IIb clinical trial of LT3001 in patients with acute ischaemic stroke. 

LT3001 met its primary endpoint of safety, with no treatment-related symptomatic intracranial haemorrhage (siCH) observed. The results showed that LT3001 maintained a favourable safety profile under an extended 24-hour treatment window and demonstrated clear functional improvement signals in large artery atherosclerosis and disabling stroke patients, supporting advancement into global Phase III development. 

Across all treatment groups, LT3001 demonstrated a consistent trend of functional improvement compared with placebo. At day 90, patients receiving LT3001 achieved a 7.3% higher rate of functional independence. 

The results, presented at the World Stroke Congress in Barcelona, Spain, also found 9% improvement in patients with moderate strokes and positive trends for patients with severe strokes, including a 4% improvement in high-dose groups. The biggest improvement came for patients with disabling strokes with arm motor drift, registering up to 24% improvement. 

The data demonstrates consistent efficacy trends across multiple clinically meaningful subgroups, supporting LT3001’s potential to improve outcomes for stroke patients who are ineligible for current reperfusion therapies. 

“LT3001 combines both thrombolytic and neuroprotective mechanisms,” said Dr Shuya Li, Chief Neurologist at Beijing Tiantan Hospital. “The Phase II results demonstrate strong potential, and we look forward to the Phase III trial further confirming its clinical benefits.” 

“LT3001 represents a completely novel drug design in stroke treatment — combining thrombolytic and neuroprotective properties into a single agent,” added Thomas Devlin, Professor of Neurology at the University of Tennessee Health Science Center and Principal Investigator of the study.  

“The positive results of this trial across numerous endpoints are particularly exciting given the unique efficacy and safety advantages of this compound within an extended treatment window.” 

Lumosa now aims to accelerate global Phase III development of LT3001 and deliver effective treatment options for stroke patients worldwide. 

 

Bruno Quinney, Content Team, DDW